About Repertoire
Repertoire is a Healthcare company based in Japan founded in 2014, and was acquired by Eurofins Scientific in May 2022. It operates as a TCR and BCR repertoire analysis services are offered. Repertoire has raised $6.47 million across 2 funding rounds from investors including Eurofins Scientific, Beyond Next Ventures and UT-EC Japan. Its chief executive is Ryuji Suzuki. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Blood Cancer. Its competitors include GSK, Avidity Biosciences, Helix, Benchling and Sutro Biopharma and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Repertoire was founded in 2014 in Ibaraki, Japan, focusing on biotechnology and immunology. Next-generation sequencing for T cell receptor (TCR) and B cell receptor (BCR) repertoires is conducted using unbiased gene amplification and proprietary bioinformatics software. Services support applications such as detection of malignant lymphoma and leukemia, identification of antigen-specific receptors, and assessment of immune checkpoint inhibitors and cancer immunotherapies. Collaborations are facilitated to advance diagnostic and therapeutic developments.
- Headquarters Ibaraki, Japan
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website repertoire.co.jp
- Social X Facebook
- Acquired by Eurofins Scientific (May 2022)
- Total Equity Funding$6.47M (USD)
in 2 rounds
- Latest Funding Round$4.77M (USD), Series B
Jul 2016
- InvestorsEurofins Scientific
& 2 more
- Acquired byEurofins Scientific
(May 2022)
Funding Insights of Repertoire
Repertoire has successfully raised a total of $6.47M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $4.77 million completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.47M
- Total Rounds 2
- Last Round Series B β $4.77M
- First Round $1.69M
(Nov 2014)
- Investors Count 2
All 2 funding rounds of Repertoire with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2016 | $4.77M | Series B | β | β | |
| Nov 2014 | $1.69M | Series A | β | β |
3 investors in total: 3 institutional.
Investors in Repertoire
Repertoire has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Eurofins Scientific, Beyond Next Ventures and UT-EC Japan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and Early stage VC firm investing in Japan | – | ut-ec.co.jp | Tokyo, Japan | |
Deep-tech investments and incubation services are provided for researchers and entrepreneurs addressing global challenges. | 2014 | beyondnextventures.com | Tokyo, Japan | |
Laboratory testing and contract research services are provided globally. | 1987 | eurofins.com | Luxembourg, Luxembourg |
Investor details for Repertoire
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Repertoire
1 people are tracked at Repertoire (1 in leadership).
| Name | Role | Group |
|---|---|---|
Ryuji Suzuki | CEO & President | Leadership |
Complete people profiles for Repertoire
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Repertoire
4 dated milestones of Repertoire across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Repertoire is founded.
- Funding First funding round of $1.7M.
- Funding Latest funding round, Series B, of $4.8M.
- Exit Acquired by Eurofins Scientific.
Competitors of Repertoire
Repertoire has 10 listed competitors in our database, 9 of them funded. They include GSK, Avidity Biosciences, Helix, Benchling and Sutro Biopharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| helix.com | 2015 | San Francisco, United States | $435M | – | Genomic database for clinical research is provided. | |
| benchling.com | 2012 | San Francisco, United States | $411.9M | 640 | Cloud-based bioinformatics platform is offered for biotech research. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. |
Detailed competitors of Repertoire
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Repertoire (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Repertoire
Complete news archive for Repertoire
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Repertoire
Repertoire was founded in 2014.
Repertoire is headquartered in Japan. It is registered at Ibaraki, Japan.
Ryuji Suzuki is the current CEO of Repertoire.
Repertoire is a funded company, having raised a total of $6.47M across 2 funding rounds to date. The company's 1st funding round was a Series A of $1.69M, raised on Nov 2014.
Repertoire was founded in 2014 in Ibaraki, Japan, focusing on biotechnology and immunology. Next-generation sequencing for T cell receptor (TCR) and B cell receptor (BCR) repertoires is conducted using unbiased gene amplification and proprietary bioinformatics software. Services support applications such as detection of malignant lymphoma and leukemia, identification of antigen-specific receptors, and assessment of immune checkpoint inhibitors and cancer immunotherapies. Collaborations are facilitated to advance diagnostic and therapeutic developments.
Repertoire's top competitors include Sutro Biopharma, Synthego and Helix.
Repertoire has 3 investors. Key investors include Eurofins Scientific, Beyond Next Ventures, and UT-EC Japan.
Yes. Repertoire was acquired by Eurofins Scientific in May 2022.